1-888-276-3030

Phenylpropanolamine (PPA)

This Litigation Has Concluded – MLG is Not Accepting New Cases

This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.

Our Involvement and Leadership

PPA was a compound that was formerly used as the active ingredient in appetite suppressants (Dexatrim® and Accutrim®) and cold medicines (Alka Seltzer®, Triaminic®, Dimetabb® etc). A seminal study (the "Yale Study") indicated an association between exposure to PPA and hemorrhagic stroke (bleeding in the brain). We were among a select group of attorneys bringing claims on behalf of people who had suffered hemorrhagic strokes after exposure to PPA. This nationwide litigation was conducted as a MDL (multi-district litigation) and assigned to U.S. District Court Judge Barbara Rothstein sitting in Seattle.

As a member of the nationwide PPA MDL Discovery Committee, we were assigned primary responsibility for conducting discovery against the two manufacturers of PPA-containing appetite suppressants, Chattem, Inc. and Delaco Corporation (formerly Thompson Medical Company). Our work against these two defendants led to the negotiation of two global settlements for our clients and approximately 400 injured people from across the country.

We served as a member of the Dexatrim MDL Negotiating Subcommittee and our seminal work in designing the early contours of a Case Scoring System provided the basis for both global settlements compensating 400 stroke victims and totaling over $170million, most of which was funded by insurance. In effecting these settlements, we served as Class Counsel in the Chattem Dexatrim Class Settlement, Class Counsel Claims Coordinator for the Chattem EDF Settlement, and Chair of the Trust Advisory Committee (TAC). appointed by the U.S. Bankruptcy Court for the Southern District of New York to oversee the Delaco Dexatrim Settlement. To our knowledge, the Delaco Dexatrim Settlement was the first pharmaceutical mass tort settlement structured as a Chapter 11 Bankruptcy Reorganization.

This Litigation Has Concluded – MLG is Not Accepting New Cases

This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.

Reasons To Hire

  1. Our Mission is Excellence
  2. Thorough and diligent review and analysis of your case
  3. Proven Track Record
  4. Excellent Legal Representation
  5. Attention to Detail
  6. Dedication to our Craft
  7. Access to Leading Experts
  8. Updates on Litigation
  9. Concern for Your Well-being as well as Your Legal Rights
  10. No Fee Unless You Recover